Lpath Inc.

Company Website

6335 Ferris Sq. Ste., A
San Diego, CA 92121

Sourcebook Data

View all the companies in Biomed & Biotech Firms - Publicly Traded*

Lpath Inc.

Market Cap as of 6/12/2015

Market Cap as of 7/03/2014


Market Cap as of 07/02/2013


Market Cap as of 06/26/2012


Market Cap as of 01/04/2012


Market Cap as of 06/20/2011


Market Cap as of 01/06/2011


Exchange and Ticker Symbol


Fields of Research

Focuses on the discovery and development of lipidomic-based therapeutic antibodies for treating human diseases primarily in the United States

Major Products

iSONEP (the ocular formulation of humanized Sphingomab)
ASONEP (the systemic formulation of humanized Sphingomab)
Lpathomab (a monoclonal antibody against lysophosphatidic acid)


Company Trade Data

Stock Symbol Close Change Volume 52-Week
Chg %Chg High Low
+ 5.00%


Scott Pancoast

  • Chief Executive Officer
  • President

Related News


Lpath announces new antibody program

Antibody developer Lpath Inc. has announced its new andibody program targeting respiratory disease.

Lpath withdraws from Pfizer process to assign iSONEP rights

San Diego's Lpath Inc. is no longer actively participating in Pfizer's process to assign the exclusive option it has for a worldwide license to develop and commercialize Lpath's iSONEP, a treatment for wet age-related macular degeneration.

Lpath receives US patent for ocular conditions

San Diego-based Lpath Inc. (Nasdaq: LPTN), a developer of bioactive lipid-targeted therapeutics, has received official notification from the U.S. Patent and Trademark Office that it has been issued another key patent supporting its iSONEP program.

Lpath reports interim results in cancer drug trial

Lpath Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, has reported interim results in its Phase 2a trial investigating the drug Asonep as a treatment for metastatic renal cell carcinoma.

Lpath kidney drug missed Phase 2 goal

San Diego biotech Lpath Inc. (Nasdaq: LPTN) reported that its Phase 2a study of Asonep for the treatment of kidney cancer did not lead to statistically significant progression-free survival in patients with advanced renal cell carcinoma.

Similar Companies

Biological Product (except Diagnostic) Manufacturing325414
Subscribe Today!